Pfizer secures EU approval for Ibrance breast cancer drug
The approval allows the company to use Ibrance in combination with an aromatase inhibitor. It also allows the use of Ibrance in combination with fulvestrant to treat women who
Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or B with inhibitors in patients aged 12 years and above.
The companies formed a clinical trial collaboration to evaluate the combination treatment. The dose-escalation part assessing IPI-549 as a monotherapy in Infinity’s phase 1 trial is continuing, and